Asuragen Press Releases
05-14-08Asuragen Launches RNARetain™, as a CE-marked In-Vitro Diagnostic Device
04-23-08Asuragen Launches Signature® LTx (Leukemia Translocation Panel) Globally
04-23-08Asuragen Launches The First Validated microRNA Diagnostic Assay
03-31-08Asuragen launches Mirna Therapeutics to Develop and Commercialize microRNA Oncology Therapeutics
03-25-08Yale and Asuragen Scientists Show that a microRNA Can Reduce Lung Cancer Growth
01-03-08Asuragen to Present at the JPMorgan 26th Annual Healthcare Conference
12-19-07Asuragen introduces Four New microRNA Services
12-10-07Asuragen, Inc. Raises $18.5 Million in Series B Financing
10-29-07 Xenomics Announces License with Asuragen for NPM1 Leukemia Diagnostics
10-23-07 Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests
10-08-07 Asuragen Licenses Roche’s Real-time Quantitative PCR Technology for Clinical Gene Expression Profilinge
08-29-07 Asuragen to Present at the Thomas Weisel Partners Healthcare Conference
08-02-07 Asuragen Launches Powerful New miRNA Analysis Tool
05-29-07 Asuragen, Inc. to provide GLP laboratory testing services to aid a Leading Biotechnology Organization
04-16-07 Agendia accesses Asuragen’s proprietary pre-analytical solution for tissue preservation...
01-10-07 Asuragen Becomes the First Certified Service Provider for Illumina Gene Expression Profiling
01-09-07 Asuragen Enters Into Licensing Agreement with Yale for Therapeutic Use of let-7 miRNA
01-03-07 Asuragen to Present at the JPMorgan 25th Annual Healthcare Conference
12-14-06 Asuragen, Inc. Achieves ISO 13485 and ISO 9001 Certification
09-11-06 Asuragen Joins Industry Leaders in Completion of the FDA MAQC Project
08-16-06 Asuragen’s microRNA Expression Profiling Service Offers Sanger miRBase 8.0 Plus New Proprietary Content
07-27-06 Asuragen Announces MicroRNA Co-Exclusive License Agreement with Max Planck Society
07-26-06 Asuragen Secures MicroRNA Licensing Agreement with Rockefeller University
06-01-06 Newly Launched Asuragen Closes Series A Funding of $49 Million